Topotarget is a Scandinavian-based late-stage clinical
development oncology company. Topotarget aims at
improving the quality of and prolonging the lives of cancer
patients by offering novel, safe, and effective cancer
drugs. Our lead compound, belinostat, is a Histone Deacetylase
(HDAC) inhibitor that
is being tested in a number of clinical trials.